Horizon Therapeutics PLC(HZNP) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Current Price

$89.88

RSI

15.829

Beta:

1.131274

February 24, 2021
1.2B
343.4M

105.013 %
33.942 %
522.354 %
143.762 %

$2,200,429,000
$1,300,029,000
$1,207,570,000
$1,056,231,000
$981,120,000
$757,044,000
69.260 %
7.657 %
14.328 %
7.656 %
29.599 %

$401,645,000
$-20,224,000
$-119,146,000
$-513,275,000
$-228,085,000
$-132,712,000
105.035 %
489.132 %
330.795 %
-55.563 %
-41.815 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.